Anti-Tumour Activity of a First-In-Class Agent NUC-1031 in Patients With Advanced Cancer: Results of a Phase I Study

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0244-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

Phase I Study of Temozolomide in Paediatric Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

Docetaxel and Cisplatin in Patients With Advanced Gastric Cancer: Results of Japanese Phase I/Ii Study

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2002English

A Phase I Study of Indoximod in Patients With Advanced Malignancies

Oncotarget
Oncology
2016English

Phase I Study of Single-Agent Ribociclib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2014English

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy